At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 39 enrolled
Drug / intervention
Liposomal Bupivacainedrug
Likely dose
Liposomal Bupivacaine 8 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients
In Brief
A Phase 4 clinical trial evaluating Liposomal Bupivacaine for Tonsillectomy and 2 related conditions. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTonsillectomy, Tonsillitis, Post-operative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartMay 1, 2015
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.1 years ago
Interventions
Liposomal Bupivacainedrug
Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.